A263050 Stock Overview
Eutilex.Co.,Ltd. discovers and develops immunomodulatory antibody therapeutics to treat cancers and autoimmune diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Eutilex.Co.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩1,866.00 |
| 52 Week High | ₩4,190.00 |
| 52 Week Low | ₩1,765.00 |
| Beta | 0.48 |
| 11 Month Change | -15.18% |
| 3 Month Change | -28.78% |
| 1 Year Change | -54.04% |
| 33 Year Change | -92.65% |
| 5 Year Change | -91.86% |
| Change since IPO | -92.83% |
Recent News & Updates
Shareholder Returns
| A263050 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -1.7% | -0.1% | -0.01% |
| 1Y | -54.0% | 22.1% | 5.0% |
Return vs Industry: A263050 underperformed the KR Biotechs industry which returned 22.1% over the past year.
Return vs Market: A263050 underperformed the KR Market which returned 5% over the past year.
Price Volatility
| A263050 volatility | |
|---|---|
| A263050 Average Weekly Movement | 5.2% |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in KR Market | 11.1% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A263050's share price has been volatile over the past 3 months.
Volatility Over Time: A263050's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 94 | Byoung S. Kwon | www.eutilex.com |
Eutilex.Co.,Ltd. discovers and develops immunomodulatory antibody therapeutics to treat cancers and autoimmune diseases. It develops anti-tumor T cell therapy and antibody therapeutics.
Eutilex.Co.,Ltd Fundamentals Summary
| A263050 fundamental statistics | |
|---|---|
| Market cap | ₩68.66b |
| Earnings (TTM) | -₩26.55b |
| Revenue (TTM) | ₩410.18m |
167.4x
P/S Ratio-2.6x
P/E RatioIs A263050 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A263050 income statement (TTM) | |
|---|---|
| Revenue | ₩410.18m |
| Cost of Revenue | ₩102.00m |
| Gross Profit | ₩308.18m |
| Other Expenses | ₩26.86b |
| Earnings | -₩26.55b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -721.53 |
| Gross Margin | 75.13% |
| Net Profit Margin | -6,472.42% |
| Debt/Equity Ratio | 16.6% |
How did A263050 perform over the long term?
See historical performance and comparison